Using Dynamic Contrast-Enhanced MRI to Predict Childrens Response to Intra-arterial Chemotherapy for Retinoblastoma

What this Trial Is About

Retinoblastoma is the most common tumor inside the eye in young children, making up 6% of pediatric cancers before age 5. The survival rate after 5 years is very high at 95 to 97%. Treatments that save the eye are increasingly used, including intra-arterial chemotherapy, which is given directly into the artery. While this treatment works for most children, some may have early disease progression. Researchers want to use a special type of MRI called dynamic contrast-enhanced MRI DCE-MRI to find factors that predict how children will respond to this chemotherapy. Children in the study will have DCE-MRI scans added to their regular MRI before starting intra-arterial chemotherapy. This imaging technique tracks blood flow and tissue changes in the eye to help predict treatment response. The study focuses on children with grade B to D retinoblastoma who are prescribed this chemotherapy treatment. There are no exclusion criteria listed. Participants will be followed for 18 months to see how they respond to chemotherapy. Researchers will evaluate the MRI results alongside treatment outcomes to identify early signs of response or progression. This observational study does not involve additional treatments but collects imaging and clinical data to improve understanding of retinoblastoma treatment response over time.

Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?